AbCellera Appoints Dr. Lynn Seely, Former Myovant CEO and Xtandi Development Lead, to Board of Directors
Key Insights
AbCellera has appointed Dr. Lynn Seely, an experienced biopharmaceutical executive, to its Board of Directors as an independent director.
Dr. Seely previously led the clinical development of Xtandi (enzalutamide) at Medivation (search) through global approvals, culminating in a $14 billion acquisition by Pfizer.
As CEO of Myovant Sciences (search), she successfully commercialized Myfembree and Orgovyx, demonstrating expertise in endocrinology and women's health.
AbCellera (Nasdaq: ABCL) today announced the appointment of Lynn Seely, M.D., to its Board of Directors as an independent director. The move brings a seasoned biopharmaceutical executive with deep experience across endocrinology, oncology, and women's health to the clinical-stage antibody discovery company as it advances multiple product candidates toward clinical development.
"Dr. Seely is a respected executive leader with a proven track record of successfully developing new medicines in endocrinology, oncology, and women's health. I am pleased to welcome her to AbCellera's Board of Directors and look forward to having her on our team," said Carl Hansen, Ph.D., founder and CEO of AbCellera.
A Career Defined by Successful Drug Development
Dr. Seely's career spans the full arc of drug development, from first-in-human trials through global regulatory approvals and commercial launches. As chief medical officer of Medivation (search) Inc., she led the clinical development of the oncology drug Xtandi (enzalutamide) from first-in-human trials through global approvals, prior to Medivation's $14 billion acquisition by Pfizer Inc.
Following her tenure at Medivation (search), Dr. Seely served as president, CEO, board member, and first employee of Myovant Sciences (search) Inc., where she successfully commercialized innovative therapies for women's and men's health, including Myfembree (relugolix, estradiol, and norethindrone acetate) and Orgovyx (relugolix).
Dr. Seely currently serves as president and CEO of Lyell Immunopharma Inc., a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors.
Board Experience and Governance
Dr. Seely brings substantial board-level experience to AbCellera. She previously served as the lead independent director for Blueprint Medicines Corp. prior to its $9.1 billion acquisition by Sanofi, and was a member of the Board of Managers for TORL BioTherapeutics LLC. She currently serves on the Board of Managers of Life Science Cares Bay Area.
"I look forward to serving on AbCellera's Board of Directors as the Company advances its mission of discovering and developing first-in-class antibody-based medicines," said Dr. Seely. "AbCellera is well positioned for growth as it moves multiple product candidates, developed by its exceptional research team and designed to bring meaningful new treatments to patients, into early- and late-stage clinical development."
Dr. Seely received her M.D. from the University of Oklahoma College of Medicine. She completed her residency and served as chief resident in internal medicine at Yale-New Haven Hospital, and completed a basic science and clinical fellowship in endocrinology and metabolism at the University of California, San Diego.
About AbCellera
AbCellera is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women's health, immunology, oncology, and more. The company's appointment of Dr. Seely underscores its commitment to strengthening governance and clinical development expertise as its pipeline progresses toward the clinic.